Long‐term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance
Open Access
- 29 June 2011
- Vol. 118 (2), 510-517
- https://doi.org/10.1002/cncr.26294
Abstract
BACKGROUND: For BRCA1/BRCA2 gene testing to benefit public health, mutation carriers must initiate appropriate risk management strategies. There has been little research examining the long‐term use and prospective predictors of the full range of risk management behaviors among women who have undergone BRCA1/2 testing. We evaluated long‐term uptake and predictors of risk‐reducing mastectomy (RRM), risk‐reducing bilateral salpingo‐oophorectomy (RRBSO), chemoprevention, and cancer screening among women at a mean of 5.3 years after testing. METHODS: The study participants comprised 465 women who underwent BRCA1/2 testing. Prior to genetic counseling, we measured family/personal cancer history, sociodemographics, perceived risk, cancer‐specific distress, and general distress. We contacted patients at a mean of 5.3 years after testing to measure use of RRM, RRBSO, chemoprevention, and breast and ovarian cancer screening. RESULTS: Among participants with intact breasts and/or ovaries at the time of testing, BRCA1/2 carriers were significantly more likely to obtain RRM (37%) and RRBSO (65%) compared with women who received uninformative (RRM, 6.8%; RRBSO, 13.3%) or negative (RRM, 0%; RRBSO, 1.9%) results. Among carriers, precounseling anxiety was associated with subsequent uptake of RRM. RRO was predicted by age. Carriers were also more likely have used breast cancer chemoprevention and have undergone magnetic resonance imaging screening. CONCLUSION: This prospective evaluation of the uptake and predictors of long‐term management outcomes provides a clearer picture of decision making in this population. At a mean of 5.3 years after testing, more than 80% of carriers had obtained RRM, RRBSO, or both, suggesting that BRCA1/2 testing is likely to have a favorable effect on breast and ovarian cancer outcomes. Cancer 2011;. © 2011 American Cancer Society.Keywords
This publication has 47 references indexed in Scilit:
- Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and MortalityJAMA, 2010
- Patient Decisions About Breast Cancer Chemoprevention: A Systematic Review and Meta-AnalysisJournal of Clinical Oncology, 2010
- Randomized Controlled Trial of a Psychosocial Telephone Counseling Intervention inBRCA1 andBRCA2 Mutation CarriersCancer Epidemiology, Biomarkers & Prevention, 2010
- Prevalence of Tamoxifen Use for Breast Cancer Chemoprevention Among U.S. WomenCancer Epidemiology, Biomarkers & Prevention, 2010
- Uptake, Time Course, and Predictors of Risk-Reducing Surgeries inBRCACarriersGenetic Testing and Molecular Biomarkers, 2009
- Randomized trial of a decision aid for BRCA1/BRCA2 mutation carriers: Impact on measures of decision making and satisfaction.Health Psychology, 2009
- Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective StudyJournal of Clinical Oncology, 2008
- International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriersInternational Journal of Cancer, 2008
- Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-upBritish Journal of Cancer, 2007
- Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivorsBreast Cancer Research and Treatment, 2006